Back to top

Image: Bigstock

Bruker (BRKR) Q1 Earnings Meet, Revenues Beat Estimates

Read MoreHide Full Article

Bruker Corporation (BRKR - Free Report) reported adjusted earnings per share (EPS) of 19 cents in the first quarter of 2017, lower than the year-ago figure by 9.5%. Adjusted EPS were in line with the Zacks Consensus Estimate.

Excluding one-time adjustments, Bruker reported net income of $21.6 million or 13 cents per share in the first quarter, reflecting a 8.5% or 7.1% decline, respectively, from the year-ago quarter.

Revenues in Detail

Bruker reported revenues of $384.9 million in the first quarter, up 2.5% year over year. The top line surpassed the Zacks Consensus Estimate of $372 million by a decent margin. Excluding a 5.3% positive effect from acquisitions and a 2.0% negative effect from changes in foreign currency rates, Bruker reported a year-over-year organic revenue decline of 0.8% in the first quarter of 2017. 

Bruker Corporation Price, Consensus and EPS Surprise

 

Bruker Corporation Price, Consensus and EPS Surprise | Bruker Corporation Quote

Geographically and currency adjusted, within Bruker’s Scientific Instruments group, European revenues declined in the mid single digits in the first quarter, reflecting soft order entry last year. North America revenues increased in the low-single digits. Asia Pacific was up double digits, including over 20% growth in China on impressive growth in both academic and industrial customer count. However, Japan was down in the low-single digits.

At constant currency, the BioSpin, B-NANO and BEST Groups saw growth, while CALID revenues declined.

The Bruker BioSpin Group reported low single-digit revenue growth, as solid NMR (Nuclear magnetic resonance) results more than offset PCI (Preclinical Imaging) revenue weakness.

The Bruker NANO reported high single-digit revenue growth, driven by Hysitron nanoindenting product's acquisition, strong growth in the semiconductor metrology tools, and enhanced results at the AXS business.  

The Bruker CALID Group reported a year-over-year revenue decline in the mid-to-high single digits in first-quarter 2017.

BEST revenues were substantially higher on a year-over-year basis, backed by the Bruker-OST acquisition in Nov 2016.

Margin Trend

Gross margin in the reported quarter expanded 140 basis points (bps) to 45.8%, while according to the company, the adjusted gross margin expanded 90 bps to 47.6%. Despite market-related volume declines, gross margin expanded on NMR price and efficiency gains along with the 2016 restructurings and factory consolidations within the Daltonics and AXS businesses of the company.

Selling, general & administrative expenses increased 5.8% to $98.1 million and research and development expenses rose 4.2% to $37.6 million from the year-ago period. The other charges declined 22.5% year over year to $3.1 million. Operating margin expanded 71 bps to 9.8%. According to the company, adjusted operating margin expanded 20 bps year over year to 12.8% due to additional expenses from the recent acquisitions of InVivo and Hysitron. Also, growth in NMR, favorable average selling prices and improved productivity contributed to the expansion in operating margin.

Financial Position

Bruker exited first-quarter 2017 with cash and cash equivalents and short-term investments of $464.5 million, down from $500.3 million at the end of 2016. The net cash provided by operating activities was $32.6 million, up from net cash used in operating activities of $14.0 million a year ago.

Adjusted free cash flow was $21.1 million in the reported quarter, compared with net cash used in operating activities of $22.0 million in the year ago quarter. A year-over-year increase in customer advances, requirement of less cash for working capital and the timing of incentive compensation payments contributed to positive free cash flow.

2017 Guidance

Bruker provided an update to its guidance for full-year 2017.

Total revenue growth rate expectation for the year has been raised to a new band of 2–3.5% from the earlier range of 1.5–2.5%. However, organic revenue growth guidance remains unchanged at 1–2% with acquisition growth is expected at 3.5–4% (unchanged).

Changes in foreign currency rates are expected to have an adverse impact on revenues of approximately 2.5%. The current Zacks Consensus Estimate for 2017 revenues is pegged at $1.65 billion.

The company also expects 2017 adjusted operating margin increase of approximately 40–70 bps year over year, unchanged from the previous guidance. This includes an approximate 40-bps headwind in fiscal 2017 from recent strategic acquisitions.  

On the bottom-line front, Bruker continues to expect adjusted EPS in the band of $1.05–$1.09. The current Zacks Consensus Estimate for 2017 EPS is pegged at $1.08.

Our Take

Bruker exited the first quarter of 2017 on a mixed note. While the company’s quarterly EPS was in line with the Zacks Consensus Estimate, revenues surpassed the mark and increased on a year-over-year basis. Meanwhile, the decline in organic revenues adds to our woes.

The company is currently focusing on product development, the latest launch being that of the AVANCE NEO platform, a next-generation NMR electronics console, which will help take NMR research to the next level. We expect this to improve the company’s competitive position.

Zacks Rank & Key Picks

Bruker currently has a Zacks Rank #3 (Hold).Better-ranked medical stocks include Hologic, Inc. (HOLX - Free Report) , Baxter International Inc. (BAX - Free Report) and Progenics Pharmaceuticals, Inc. . Hologic, and Progenics Pharmaceuticals sport a Zacks Rank #1 (Strong Buy), while Baxter International carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Hologic gained 33.6% in the last one year, in comparison to the S&P 500’s 16.6%. The company has a stellar four-quarter average earnings surprise of over 4.16%.

Baxter International rose around 23.4% in the last one year, in comparison to the S&P 500. It has a four-quarter average earnings surprise of 17.14%.

Progenics Pharmaceuticals gained 56.6% in the past one year, better than the S&P 500 mark. It has a four-quarter average earnings surprise of 8.45%.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Baxter International Inc. (BAX) - free report >>

Hologic, Inc. (HOLX) - free report >>

Bruker Corporation (BRKR) - free report >>

Published in